SLC9A1 and metabolic acidosis: Thus, our demonstration of whole body protective actions by a potent selective NHE1 inhibitor in a setting of global metabolic acidosis in vivo should lead to a refocus of the therapeutic potential of NHE1 inhibitors: a whole body protection from systemic metabolic acidosis.